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Introduction
It was six men of Hindustan
To learning much inclined,
Who went to see the Elephant
(Though all of them were blind), 
That each by observation 
Might satisfy his mind…
And so these men of Hindustan
Disputed loud and long, 
Each in his own opinion
Exceeding stiff and strong, 
Though each was partly in the right 
And all were in the wrong.
An extract from The Blind Men and the
Elephant by John Godfrey Saxe 
(1816-1887)
Use of the mouse as a model organism has
proved to be one of the most powerful
approaches available in our efforts to
understand and cure human disease
(Sundberg, 1991; Peters et al., 2007;
Rosenthal and Brown, 2007). Mutant mice
not only provide models for major aspects
of disease, serving as preclinical tools for
drug discovery and efficacy testing
(Zambrowicz and Sands, 2003; Zambrowicz
et al., 2003a; Antony et al., 2011; Sutherland
and Berns, 2011; Van Dam and De Deyn,
2011), but the phenotyping of spontaneous
and genetically engineered mutant mice
also generates a great deal of fundamental
information about gene function that can
then be used to explore the underlying
pathobiology.
Through hypothesis-driven research and
the use of spontaneous and induced
mutations, we now have at least partial
phenotypic information on just over a third
of the ~25,000 mouse genes with associated
protein sequence data (see Box 1). The
remainder of the genome remains closed to
us, a black box that can be accurately
characterised as the ‘ignorome’ – that set of
protein-coding genes about which we know
little apart from their genomic location and
predicted exon structure. Within the
ignorome lie thousands of genes whose
functions hold the answer to many questions
about normal physiology and disease; a major
challenge of the 21st century is how we can
most efficiently gain traction on this problem
and create an ‘encyclopaedia’ of gene
function for every gene in the genome. Over
the last decade, whole-genome approaches
for the discovery of gene function and new
models of human disease have been
developed using the mouse. These have been
either phenotype driven – using ENU
mutagenesis (Munroe et al., 2000; Acevedo-
Arozena et al., 2008), gene trapping (Hansen
et al., 2008) or insertional mutagenesis (Ivics
et al., 2009) – or genotype driven through the
use of targeted knockouts (Skarnes et al.,
2011). All of these approaches require the use
of high-throughput phenotyping pipelines
(see Box 2) to characterise large numbers of
animals for a wide range of phenotypic
parameters; for example, the German Mouse
Clinic measures more than 550 parameters
in two cohorts of ten mice of each sex and
genotype (Fuchs et al., 2009; Fuchs et al.,
2010; Gates et al., 2010; Gailus-Durner et al.,
2011). High-throughput phenotyping
pipelines are central to the recently launched
International Mouse Phenotyping
Consortium (IMPC) project
(http://www.mousephenotype.org), which
has set out to phenotype knockouts for every
protein coding gene in the mouse genome
(Abbott, 2010). These pipelines have also
been implemented in discovery strategies in
the pharmaceutical industry and other major
academic laboratories.
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Exploring the elephant: histopathology in 
high-throughput phenotyping of mutant mice
Paul N. Schofield1,2,*, Peter Vogel3, Georgios V. Gkoutos4 and John P. Sundberg2
Recent advances in gene knockout techniques and the in vivo analysis of mutant
mice, together with the advent of large-scale projects for systematic mouse
mutagenesis and genome-wide phenotyping, have allowed the creation of
platforms for the most complete and systematic analysis of gene function ever
undertaken in a vertebrate. The development of high-throughput phenotyping
pipelines for these and other large-scale projects allows investigators to search
and integrate large amounts of directly comparable phenotype data from many
mutants, on a genomic scale, to help develop and test new hypotheses about the
origins of disease and the normal functions of genes in the organism.
Histopathology has a venerable history in the understanding of the pathobiology
of human and animal disease, and presents complementary advantages and
challenges to in vivo phenotyping. In this review, we present evidence for the
unique contribution that histopathology can make to a large-scale phenotyping
effort, using examples from past and current programmes at Lexicon
Pharmaceuticals and The Jackson Laboratory, and critically assess the role of
histopathology analysis in high-throughput phenotyping pipelines.
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In this Special Article, we explore the
implementation and value of histopatholog-
ical analysis in high-throughput mouse
phenotyping pipelines, its complementarity
to in vivo assays, and its unique contribution
to our understanding of disease.
Histopathology as a component of
high-throughput phenotyping
pipelines
Histopathology is the systematic and
systemic analysis of the microscopic
morphological correlates of disease through
examining tissues obtained from necropsy or
biopsy under the microscope. Macroscopic
(gross) analysis is sometimes referred to as
anatomic pathology, although this term is
more properly used to denote the whole
discipline or medical specialty. In the current
context, the pathologist examines a mouse
at both micro- and macroscopic levels.
Histopathology is indispensable for any high-
throughput phenotype screening programme
because it can identify phenotypes not
detected by any other physiological or
behavioural screening assays and provide
contextualisation for in vivo findings. It also
provides an overview of the disease processes
ongoing in the whole organism and aids the
interpretation of in vivo assays, such as blood
cell counts, urinalysis and gait, etc. Like the
elephant in the poem by John Saxe quoted
above, examining only part of a phenotype,
however precisely, is likely to lead to serious
errors; thus, the whole phenotype must be
characterised to obtain an accurate
description.
Along with the development and stan-
dardisation of physiological and in vivo
phenotyping methodologies over the last
decade, considerable experience has been
accumulated of the use of high-throughput
histopathology for the characterisation of
mice from systematic screening
programmes in both academia and the
pharmaceutical industry (Beltrandelrio et
al., 2003; Sundberg and Ichiki, 2005; Yuan
et al., 2009). The German Mouse Clinic, for
example, has included histopathology in its
pipeline since 2001 (Fuchs et al., 2009;
Gailus-Durner et al., 2009; Fuchs et al.,
2010), and the Toronto Centre for
Phenogenomics runs histopathological
analysis as an integral part of its
phenotyping pipeline. Other centres have
used detailed histological phenotyping for
several decades as a standard first screen for
defining mouse models of human diseases,
using the physiological methods described
above as confirmatory assays only as needed
(Sundberg and Boggess, 1998; Sundberg et
al., 2000; Sundberg et al., 2011). At a recent
meeting in Bordeaux, France, which was
organised under the auspices of EUMODIC
(European Mouse Disease Clinic) and the
Cancéropôle Grand Sud-Ouest, a group of
pathologists and geneticists from academia
and industry critically examined the
advantages and problems associated with
various approaches to running high-
throughput histopathology phenotyping
(Schofield et al., 2011); the reader is referred
to this source for additional discussion and
insights from a wide range of experiences.
High-throughput histopathology
phenotyping in drug discovery
Evidence that the pathological processes
underlying the abnormal phenotypes of
knockout mice often mirror the therapeutic
targets of many drugs in humans has spurred
the use of knockout mice in drug discovery
research (Zambrowicz and Sands, 2003). In
the past decade, pharmaceutical companies
have developed and utilised comprehensive
high-throughput phenotype screening
protocols to identify potentially useful drug
targets and toxicity liabilities in genetically
engineered mice. Because a primary
objective of pharmaceutical companies is to
discover drug targets and any related risks in
the most timely and cost-effective manner
possible, we believe that their approaches to
phenotyping can serve as useful templates in
designing a rational and cost-effective
approach to high-throughput phenotyping of
knockout mice in other research settings.
In order to recoup the considerable
investment made in generating a new line of
genetically engineered mice, comprehensive
phenotyping programmes are used in
pharmaceutical development to ensure that
unexpected and valuable phenotypes are not
missed. Experience has shown that
phenotype screening programmes must be
comprehensive because completely novel
and unexpected phenotypes seem to appear
at least as often as those predicted by specific
hypotheses. The phenotyping protocols used
in the pharmaceutical industry are usually
performed in a centralised facility, and
include assays that permit the rapid and
cost-effective assessment of a wide range of
physiological parameters. They are generally
restricted to a carefully selected and validated
battery of rapid and relatively straightforward
physiological and behavioural assays.
In a programme at Lexicon
Pharmaceuticals, which generated and
analysed over 4650 knockout mouse lines in
a high-throughput mutagenesis and
phenotyping process that was designed to
characterise protein functions and identify
novel drug targets (Zambrowicz et al., 2003b;
Zambrowicz et al., 2003a), many phenotypes
were discovered that have proven useful in
elucidating fundamental processes in biology
and the pathogenesis of disease. Important
phenotypes would have been missed if the
use of histopathology in high-throughput
screening had been restricted only to those
lines showing early mortality or other
physiological or behavioural phenotypes,
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Box 1. Functional characterisation of the mouse genome
Data from the Mouse Genome Database (Blake et al., 2011) currently (October 2011) lists 15,226 genes
with mutant alleles in mice, and phenotypic information is currently available for ~8200 of the
~25,000 mouse genes with associated protein sequence data. At the level of protein class or Gene
Ontology (GO) molecular function annotation, we only have 13,591 genes with any experimentally
based functional annotations and, of the 8600 GO molecular function terms, most have very few
associated gene products. Only 7000 genes have GO-biological process annotations in the mouse.
Box 2. What is a high-throughput phenotyping pipeline?
Phenotyping pipelines comprise a series of sequential assays carried out on the same cohort of mice;
these assays measure a broad set of phenotypic parameters, with a high rate of throughput. The
breadth of these predominantly in vivo assays is key to the pipeline approach, which is designed to
detect a wide spectrum of phenotypes ranging, for example, from behaviour to dysmorphology,
clinical chemistry and immune responses (Justice, 2008; Mandillo et al., 2008; Brown et al., 2009; Gates
et al., 2010). The complexity of phenotypes assayed is directly proportional to the cost and inversely
proportional to throughput; as assays become more labour intensive, the number of mice that can
feasibly be examined decreases. This then requires the stratification of assays into primary, secondary
and tertiary phenotyping efforts, whereby mice from the primary pipeline are selected for additional
in-depth analysis on the basis of phenotypes uncovered in the first battery of assays.
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emphasising the importance of
histopathology in a primary screen. Even in
those cases in which a phenotype was initially
identified with another screening test,
histopathology findings were invaluable in
elucidating the underlying structural basis for
physiological or behavioural phenotypes.
Below, we provide some examples of the
value of histopathological analysis in high-
throughput screens used in evaluating
knockout mouse lines at Lexicon.
Case studies from high-throughput
histopathological analysis
Advantages of the systemic
approach
In many knockout lines, histopathology has
proved to be the most efficient and precise
method to detect phenotypes in speciﬁc
organ systems, including the upper
respiratory tract, teeth, eyes, muscle, kidney
and skin. In fact, in the Lexicon screen,
histopathology was the only assay included
in a comprehensive battery of tests that
revealed a phenotype in many knockout
lines. For example, although some tooth
abnormalities are grossly visible, most
reported tooth phenotypes require
histopathology for full characterisation (Bei,
2009), and several knockout phenotypes were
characterized by significant enamel or dentin
defects that were only detected histologically
(P.V., unpublished observations). Detection of
tooth phenotypes by histopathology is rapid
and cost effective because the cross-sections
of the nose that are included in standard
histopathology tissue sets include incisor
and molar teeth in addition to the nasal
passageways. Evaluation of these nasal
sections also permits rapid diagnosis of
primary ciliary dyskinesia in mice, which can
also be characterised by male infertility and
hydrocephalus, but most commonly presents
as a clinically asymptomatic suppurative
rhinosinusitis that is best detected by
histological evaluation of nasal passageways
(Vogel et al., 2010a).
The eye is another organ system in which
histopathological evaluation provides unique
advantages. Although many ocular defects
can be detected by a combination of
fundoscopy, angiography and intraocular
pressure measurements, virtually all of these
defects can be diagnosed less expensively and
more definitively by histopathology (Smith et
al., 2002). More importantly, the earliest
lesions in many types of progressive retinal
degeneration can only be detected by
histopathology, so this technique is of crucial
importance in high-throughput phenotyping
because cost constraints generally require the
use of relatively young mice. Interestingly, we
also found that pigmentation defects are
most easily assessed in the eye, where the
close proximity of both neural-crest-derived
melanocytes and pigmented neuroepithelial
cells allows direct comparisons. This unique
arrangement can accentuate differences in
pigmentation and in fact led directly to the
identification of an important hypopigmen-
tation gene (Slc24a5) in mice that had not
been found previously among any of the
hundreds of pigment variants present in this
organism. The effects of Slc24a5 on
pigmentation had been missed previously
because mutation of this gene does not have
any grossly detectable effects on hair coat
colour (Vogel et al., 2008). Although
screening tests to detect lighter skin in mice
could be developed to find additional
pigmentation genes, these assays would be
more time consuming and expensive than
histological evaluation of eye pigmentation.
Early discovery of age-related
degenerative and neoplastic
phenotypes
Another important advantage provided by
inclusion of histopathology in initial
phenotype screens is that many phenotypes
can be identified histologically before
behavioural or physiological abnormalities
are detectable. High-throughput
phenotyping is generally performed on
young mice in order to reduce husbandry
costs, but it is clear that age-related
phenotypes are missed when only young
mice are examined, because these mice are
at a stage when age-related phenotypes might
not be sufficiently developed to cause
metabolic, morphological or behavioural
problems (Myers, 1978; Bronson, 1990; Mohr
et al., 1996; Lipman, 1997).
As mentioned above, retinal degeneration
can be readily detected by histopathology in
young mice. In addition, we found that an
increased frequency of hepatocyte mitoses
detected in otherwise normal young mice is
a reliable predictor of liver disease and early
onset hepatic neoplasms (Read et al., 2009).
Similarly, numerous ubiquitin-positive
eosinophilic bodies were detected in the
deep cerebellar and vestibular nuclei of young
Atg4b-deficient mice [Atg4bGt(OST264114)Lex]
(Read et al., 2011) long before they showed
the measurable impairment of motor
performance caused by knocking out this
gene. In several other lines, widespread
centralisation of myocyte nuclei was seen
without detectable muscle weakness, high
serum creatine kinase levels or prominent
inflammatory infiltrates, demonstrating a
muscle phenotype that was not revealed at
this stage of the disease by physiological
assays. Others have shown that evaluation of
the diaphragm muscle can permit early
detection of myopathies that would
otherwise go undetected in young mice
(Barton et al., 2010).
As noted previously, because
histopathology encompasses evaluation of the
whole animal, genetic defects can result in a
characteristic pattern of lesions in multiple cell
and tissue types that, when found in other
lines of knockout mice, facilitate the
recognition of previously unsuspected
relationships between genes. Separate lines of
knockout mice with similar pathological
phenotypes have facilitated the discovery of
important pathogenetic mechanisms, ligand-
receptor pairs, cofactors or proteins located
along the same metabolic pathways. For
example, the frequent association in many
lines of knockout mice of hydrocephalus
(accumulation of cerebrospinal fluid in the
cerebral ventricles) with chronic upper
respiratory lesions caused by deficient ciliary
clearance clearly demonstrated that
dysfunctional motile cilia on ependymal cells
were central to the pathogenesis of this
devastating neurological condition (Vogel et
al., 2010a; Vogel et al., 2010b).
In another case, finding lesions in two
knockout lines of mice deficient for the
enzymes that were later determined to be
responsible for mucolipidosis (ML) types II
and IIIC illustrates how histopathology can
detect otherwise hidden phenotypes, identify
genes with related functions and even
elucidate fundamental pathogenetic
processes (Vogel et al., 2009). With the
exception of histopathology, no notable
phenotypes were detected in a line of N-
acetylglucosamine-1-phosphotransferase, 
subunit knockout mice (Gnptgtm1Lex/
Gnptgtm1Lex) that had been subjected to
comprehensive phenotypic analysis involving
a wide array of tests. However, histopatho-
logical evaluation of tissues 
from these asymptomatic mice revealed
widespread cytoplasmic vacuolisation and
inclusions in secretory cells in several
glandular tissues. We had previously seen a
very similar disease phenotype in secretory
Disease Models & Mechanisms 21
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cells in Gnptab (subunits /) homozygous
knockout mice [GnptabGt(OST97730)Lex]. The
many similarities alerted us to the fact that
the genes involved in these two lines were
related, and it was later found that the
affected genes encode different subunits of
the same enzyme complex, and that
mutations in these subunits had been linked
to the development of MLII and MLIII in
humans. Notably, neither line of mutant mice
developed the skeletal and connective tissue
abnormalities or the vacuolar cytoplasmic
alterations in fibrocytes or mesenchymal
cells that characterise the lesions of ML in
humans. Instead, the predominant lesions in
both lines of mice were found in the secretory
epithelial cells of several exocrine glands,
including the pancreas and the parotid,
submandibular salivary, nasal, lacrimal,
bulbourethral and gastric glands. We initially
believed that mice lacking either the ,  or
 subunits displayed clinical and pathological
features that differed substantially from those
reported in humans having mutations in
orthologous genes, but then found a single
report describing similar findings in
secretory cells of the exocrine pancreas,
salivary glands and gastric chief cells in
patients with MLII (Elleder and Martin,
1998). The significance of these earlier
findings was not fully appreciated until the
pathological phenotypes in knockout mice
were published (Gelfman et al., 2007; Vogel
et al., 2009).
Together, these papers support a novel
hypothesis that implicates secretory
dysfunction rather than a classic lysosomal
storage disease in the pathogenesis of the
connective tissue (bone and collagen) lesions
seen in human MLII and MLIII.
Chondrocytes and fibroblasts are not
generally thought of as secretory cells, but
they do secrete large amounts of collagen and
cartilage matrix during periods of rapid
growth. The novel insights into the
pathogenesis of these diseases in the mouse
have contributed to additional investigations
into the underlying pathobiology in humans
(Flanagan-Steet et al., 2009; Boonen et al.,
2011), and serve as an example of the
advances made possible through
histopathology phenotyping of seemingly
normal knockout mice.
Histopathology contextualises 
in vivo findings
So far, we have provided examples that
illustrate the indispensable role of
histopathology as a first-order assay in
discovering gene function. The in vivo assays
in a pipeline are designed to detect a wide
range of phenotypes, but each assay probes
a specific aspect of the phenome and in few
cases do assays provide definitive diagnostic
or aetiological information about the overall
disease process in the whole organism. The
ancient Buddhist story referred to in Saxe’s
poem is an excellent metaphor for this – that
is, that each assay probes and evaluates a
different part of the ‘elephant’. Unfortunately,
this means that striking findings in a single
assay can be misleading to investigators if
taken out of context. In histopathology
evaluations, the microscopic structure of
virtually every organ system is considered
and findings are noted in the context of the
whole animal. Histopathology is therefore
well equipped to provide a context for
abnormal findings obtained from other
physiological and behavioural assays, and
can facilitate the integration of all findings
to give a more complete and accurate picture
of the knockout phenotype. For example,
blood pressure is a physiological parameter
commonly measured in high-throughput
screening, with the intent to discover
potential drug targets for treating
hypertension. In some cases, histopatholog-
ical evaluation has proven invaluable in
determining whether underlying structural
defects in the myocardium or other problems
are responsible for the low blood pressure
readings (Van Sligtenhorst et al., 2011).
Similarly, drug target discovery screening
for osteoporosis relies on bone density
measurements provided by techniques such
as microCT assay. However, histopathologi-
cal evaluation of bone sections can quickly
and reliably indicate whether the measured
increases in bone density are likely to result
in increased bone strength (as in sclerostin
knockout mice) (Li et al., 2008) or increased
bone fragility (as in cathepsin-K knockout
mice) (Li et al., 2006). Yet another line of
knockout mice showing increased bone
density concurrently displayed a desirable
lean phenotype by whole body dual-energy
X-ray absorptiometry (DEXA) scans and
body weight measurements. Histopathology
confirmed the increased bone density but
also revealed the presence of defects in tooth
dentin accompanied by severe periodontal
inflammation, which provided a contextual
explanation for the lean phenotype (P.V.,
unpublished observations). In other cases,
histopathology showed that other knockout
lines found to have low body weight or lean
phenotypes using physiological
measurements had other precipitating
causes, including protein-losing glomeru-
lopathies or enteropathies, and
malabsorption syndromes.
Cost-effectiveness of
histopathology screening
One major challenge facing the field of
functional genomics is the need to accurately
determine the in vivo function of all genes
in the most timely and cost-effective manner
possible. Histopathology is not inherently a
rapid or inexpensive assay, but the power of
this ‘whole animal’ method of evaluation
makes it an essential component of any high-
throughput screening programme. The
successful inclusion of histopathology in
phenotyping screening programmes used in
pharmaceutical drug discovery efforts proves
that it is both worthwhile and possible to
control the costs of histopathology
evaluation, thereby reducing the numbers of
missed phenotypes (false negatives). In the
setting of a pharmaceutical programme, the
cost effectiveness of every assay included in
a testing regimen is evaluated continuously,
and only those that contribute significantly
to the drug development process are
continued. As a result, very strong
justification is required to incorporate and
continue any labour-intensive or time-
consuming assay as part of a high-
throughput phenotyping screen. It is
therefore noteworthy that histopathology
phenotyping – which is both labour intensive
and time consuming – was always included
in the battery of primary screening assays
used in evaluating knockout mice lines at
both Genentech and Lexicon
Pharmaceuticals.
A major cost driver in many proposed
histopathology screens is the large number
of knockout mice and wild-type controls
often said to be needed. However, based on
our experience of phenotyping over 4500
lines, it is unnecessary to include wild-type
control mice with every knockout line,
provided knockout mice are generated on a
standard genetic background. In fact, the
numbers of wild-type mice evaluated can be
further reduced over time as pathologists
gain experience with the lines used. The
relatively low numbers of mice (two males
and two females) proposed for use in an
initial screen is based on our experience of
performing histopathology phenotyping on
dmm.biologists.org22
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472 lines of knockout mice with targeted
mutations in transmembrane and secreted
proteins (Tang et al., 2010). Interestingly, over
100 of these lines had previously been
evaluated by pathologists following a
protocol that allowed only two knockout
mice (one male and one female) in the initial
screen, with provision for additional mice to
be tested in cases in which suspected
pathology phenotypes were found. Among
these 100 lines, only one additional
phenotype was detected by doubling the
number of mice evaluated, and in this lone
exception (Pkd1l1tm1Lex homozygous
knockout mice) (Vogel et al., 2010c) the only
additional phenotype noted that was missed
on initial evaluation was situs inversus
(reversed orientation of internal organs),
which was present in less than 50% of mice
lacking the gene.
On the basis of prior experience, it is likely
that a rapid, accurate and cost-effective
histopathological screen will require a
minimum of two males and two female
knockout mice; the establishment of uniform
tissue collection, fixation and processing
methods; and the evaluation of tissue
sections by pathologists with expertise in
specific organ systems. The standardisation
of tissue collection, fixation and processing
procedures is essential to control costs while
improving efficiency and simultaneously
ensuring top quality histopathological
evaluations. Nevertheless, the key
requirement for keeping the costs of
histopathology low while keeping the quality
and reliability of findings high is to have
expert pathologists perform the evaluations.
There are several reasons for this. An expert
can very quickly recognise subtle but real
lesions in a specific tissue that even an
experienced pathologist might miss or need
additional time to research and understand.
In addition, an expert will already be familiar
with and quickly identify incidental or
background changes of no consequence that
sometimes occur in individual mice (thereby
reducing the number of false positives and
time). Having inexperienced pathologists or
post-docs perform pathology screening will
inevitably increase the numbers of both
missed (false-negative) and spurious (false-
positive) phenotypes.
Training in the specialist area of mutant
mouse pathology has received much
discussion in recent years, with considerable
concern about the availability of qualified and
experienced pathologists (Barthold et al.,
2007; Schofield et al., 2009). Recent
investment in training programmes in France
(Schofield et al., 2011) and the emergence of
courses associated with the Centre for
Genomic Pathology (http://ctrgenpath.net/)
in the United States, together with existing
programmes (Sundberg et al., 2007;
Sundberg et al., 2010), are cause for
optimism. These developments reflect a
renewed interest among young veterinary
pathologists in this new and expanding area,
although further momentum needs to be
built and maintained.
Histopathology and informatics
It is difficult to make a quantitative estimate
of the relative value of histopathology versus
in vivo phenotyping to the overall use of
phenotype data. We believe that the
examples discussed above more than
adequately demonstrate the scientific value
of such phenotyping. Recently, however, the
development of the mammalian and human
phenotype ontologies (Robinson et al., 2008;
Smith and Eppig, 2009) – which describe
phenotypes associated with mouse mutants
or human diseases – has allowed us to
quantitatively estimate the usefulness of
different types of mouse phenotype data in
discovering candidates for human diseases.
The graph shown in Fig. 1 represents the
information content (IC; i.e. the
discriminating ability) of terms in the
mammalian phenotype ontology that contain
pathology information (red bars), mapped
onto the total disease information in Online
Mendelian Inheritance in Man (OMIM; blue
bars). It is clear that the phenotype ontology
terms involving histopathology occupy a
position at the upper end of the IC (Shannon,
1948) spectrum compared with most in-
vivo-measured phenotypes, and thus will be
much more powerful for finding related
phenotypes in mice and humans.
The use of standardised nomenclature for
lesions, based on accepted ontologies such
as the mammalian pathology ontology
(MPATH) (Schofield et al., 2010a), should be
an absolute requirement for data capture
from high-throughput pathology
phenotyping. Standardised nomenclature
not only facilitates the retrieval of data shared
through public databases, but also allows
quantitative analysis of phenotyping
Disease Models & Mechanisms 23
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Fig. 1. Information content (IC) of mammalian phenotype ontology terms in the OMIM dataset. Blue
columns represent all phenotype ontology terms and red columns those terms that are defined using
terms from the mammalian pathology ontology (MPATH). Mammalian phenotype ontology terms were
used to automatically annotate all OMIM diseases by mapping between the human and mammalian
phenotype ontology with PhenomeBlast software (http://bioonto.gen.cam.ac.uk:9090/PhenomeBlast-
0.1/). The IC was then calculated as the probability that a given ontology term is used in the annotation of
an OMIM disease. For example, abnormal circulating lipid level (MP:0003949) is a relatively
undiscriminating measurement because it is found as an annotation to 430 OMIM diseases; thus, the IC
for this term is low. By contrast, xanthoma (deposition of cholesterol-rich lipids under the skin;
MP:0003692) has a much greater ability to discriminate between diseases because it is only found in 17
diseases in OMIM, and the IC for this term is high. Less than 10% of the phenotype ontology terms are
defined using MPATH, but the spectrum of IC values shows that terms defined using MPATH are more
informative and therefore more discriminating than the bulk of the phenotype ontology terms.
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experiments (Sundberg et al., 2011) and
permits the use of this data for bioinformatic
approaches that aim to discover human
disease genes (Schofield et al., 2010b) by
allowing the computational analysis of data
from human and mouse phenotype
knowledgebases (Washington et al., 2009;
Hoehndorf et al., 2011).
Conclusions
Experience gained over the last decade from
the use of histopathological analysis in high-
throughput mouse phenotyping programmes
provides insights into its power and com-
plementarity to in vivo phenotyping assays.
High-throughput histopathology is
logistically feasible and can detect
phenotypes that other assays are unable to
identify, especially the early-onset aspects of
age-related disease that do not manifest as
physiological or behavioural perturbations at
the age when in vivo assays are conducted.
This is particularly important because most
phenotyping pipelines use mice that are less
than 20 weeks of age for reasons of cost.
Importantly, histopathological analysis
needs to be carried out by experts to be
reliable, and the availability of pathologists
with sufficient experience of genetically
engineered mice is frequently a concern.
Acknowledgement of the importance of this
expertise by funding agencies and new
training programmes in some countries, as
well as renewed enthusiasm for the specialty
by trainees, bode well for the future, although
more investment is needed. We believe,
however, that the availability of experienced
pathologists is unlikely to be the limiting
factor in setting up high-throughput
pathology programmes at the moment. In
addition, the situation has been helped by the
maturation of whole-slide scanning and
viewing technologies, which provide a viable
way to share expertise and data internation-
ally (Potts, 2009), making the most of the
global pool of expertise.
Standardisation of terminologies and the
adoption of defined ontologies also enhance
the ability to share and combine data, and to
use computation to relate phenotypes
derived from histopathological analysis to
human disease. Propagation and
development of these standards, together
with training in basic informatics for
pathologists, would add still further to the
efficiency and usefulness of the approach.
When Nusslein-Vollhard and Wieschaus
first conducted their saturation mutagenesis
screen of Drosophila in the late 1970s, the
prospect of having a phenotypic characteri-
sation for a mutation in every gene in a
mammal seemed distant to the point of being
unattainable. In the case of flies, the
phenotypes came first and then the
sequences, with the fruit fly genome being
announced complete in 2000. The complete
genome sequence of the mouse was available
before the large-scale mutagenesis projects
began (Mouse Genome Sequencing
Consortium, 2002); it is owing to the
combination of having the complete genomic
sequence, advances in targeted mutagenesis
and the development of high-throughput
technologies that we are now looking at the
prospect of completion of a systematic
encyclopaedia of gene function for the
Mouse Genome by 2021 through the IMPC
project. The inclusion of gross pathology and
histopathology in the recommendations for
phenotyping in this – the largest project of
its kind ever undertaken – will contribute not
only to our interpretation of the in vivo
assays planned, but will also improve our
ability to discover and understand mouse
models of human disease.
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